Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Prostate Cancer

  Free Subscription


12.10.2026

4 BJU Int
1 BMC Cancer
1 Br J Cancer
1 Clin Cancer Res
1 Eur Radiol
13 Eur Urol
2 Int J Urol
1 J Clin Oncol
1 J Nucl Med
3 J Urol
1 PLoS One
2 Prostate
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. TAKAHASHI T
    Active surveillance for prostate cancer: evidence interpretation and research priorities.
    BJU Int. 2026 Oct 8. doi: 10.1111/bju.70486.
    PubMed        

  2. NATHAN A, Parry MG, Mayne E, Cook A, et al
    Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study.
    BJU Int. 2026 Oct 8. doi: 10.1111/bju.70432.
    PubMed        

  3. XIAO X, Ni X, Zhao Y, Li X, et al
    Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials.
    BJU Int. 2026 Oct 5. doi: 10.1111/bju.70474.
    PubMed         Abstract available

  4. FLETCHER SA, Pickersgill NA, Aiken N, Assel MJ, et al
    Gleason pattern 4 length and active surveillance eligibility in Grade Group 2-4 prostate cancer.
    BJU Int. 2026 Oct 4. doi: 10.1111/bju.70478.
    PubMed         Abstract available


    BMC Cancer

  5. WANG Y, Fu G, Han D, Ye D, et al
    A novel "early warning" system for biochemical recurrence in prostate cancer: development and validation of the SII-HALP combined score.
    BMC Cancer. 2026;26:1204.
    PubMed         Abstract available


    Br J Cancer

  6. HANSEN EB, Antonsen KW, Jochumsen MR, Salachan PV, et al
    Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163.
    Br J Cancer. 2026 Oct 6. doi: 10.1038/s41416-026-03633.
    PubMed         Abstract available


    Clin Cancer Res

  7. HONG BH, Olabumuyi AA, Zhao SG, Trivedi P, et al
    Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer.
    Clin Cancer Res. 2026 Oct 8. doi: 10.1158/1078-0432.CCR-26-2269.
    PubMed         Abstract available


    Eur Radiol

  8. POOCH E, Agrotis G, Schoots IG, Emberton M, et al
    Critical appraisal of artificial intelligence studies for prostate cancer detection on MRI.
    Eur Radiol. 2026 Oct 7. doi: 10.1007/s00330-026-12915.
    PubMed         Abstract available


    Eur Urol

  9. EL-TAJI O, Dutey-Magni P, Brown M, Murray M, et al
    Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial.
    Eur Urol. 2026 Oct 6:S0302-2838(26)02370-5. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available

  10. STABILE A, Quarta L, Scilipoti P, Deho F, et al
    Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. In press. https://doi.org/
    Eur Urol. 2026 Oct 5:S0302-2838(26)02416-4. doi: 10.1016/j.eururo.2026.
    PubMed        

  11. HINDIE E, Callaud A, Morgat C
    Re: Sobia Khan, Nathan Papa, Andrew Kneebone, et al. Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium [(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Uro
    Eur Urol. 2026 Oct 3:S0302-2838(26)02417-6. doi: 10.1016/j.eururo.2026.
    PubMed        

  12. MEIER R, Aghdam N, Kaplan I
    Reply to Paolo Zaurito's Letter to the Editor re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. htt
    Eur Urol. 2026 Oct 3:S0302-2838(26)02367-5. doi: 10.1016/j.eururo.2026.
    PubMed        

  13. HE BM, Wang HF
    Reply to Riccardo Lombardo's Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferio
    Eur Urol. 2026 Oct 3:S0302-2838(26)02414-0. doi: 10.1016/j.eururo.2026.
    PubMed        

  14. BELLIVEAU C, Saad F, Duplan D, Petit C, et al
    PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.
    Eur Urol. 2026 Oct 3:S0302-2838(26)02413-9. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available

  15. HEMENWAY GM, Geynisman DM
    Re: Perioperative Apalutamide in High-risk Localized Prostate Cancer.
    Eur Urol. 2026 Oct 3:S0302-2838(26)02380-8. doi: 10.1016/j.eururo.2026.
    PubMed        

  16. GIROMETTI R, Giganti F
    Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial.
    Eur Urol. 2026 Oct 3:S0302-2838(26)02378-X. doi: 10.1016/j.eururo.2026.
    PubMed        

  17. COOPER S, Patel J, Moore C, Ostler P, et al
    Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.
    Eur Urol. 2026;90:321-327.
    PubMed         Abstract available

  18. EMMETT L, Papa N, Sartor O, Morris MJ, et al
    Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [(177)Lu] Lu-PSMA-617 (ANZUP1901).
    Eur Urol. 2026;90:333-343.
    PubMed         Abstract available

  19. GRECO F
    Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study.
    Eur Urol. 2026 Oct 6:S0302-2838(26)02379-1. doi: 10.1016/j.eururo.2026.
    PubMed        

  20. COOPERBERG MR
    Re: Perioperative Apalutamide In High-risk Localized Prostate Cancer.
    Eur Urol. 2026 Oct 6:S0302-2838(26)02323-7. doi: 10.1016/j.eururo.2026.
    PubMed        

  21. HE BM, Wang HF
    Reply to Dachun Jin, Chi-Fai Ng, and Peter Ka-Fung Chiu's Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multic
    Eur Urol. 2026 Oct 9:S0302-2838(26)02415-2. doi: 10.1016/j.eururo.2026.
    PubMed        


    Int J Urol

  22. IWAMOTO H, Izumi K, Machioka K, Toriumi R, et al
    Treatment-Effect Heterogeneity and a Simple Framework for Estimating Survival Benefit Associated With Local Therapy in Nonmetastatic Advanced Prostate Cancer: A Multicenter KAMU-ON Cohort Study.
    Int J Urol. 2026;33:e70668.
    PubMed         Abstract available

  23. NAKAI Y, Onishi K, Miyake M, Yamaki K, et al
    Younger Age Is Associated With Slower PSA Decline After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer.
    Int J Urol. 2026;33:e70653.
    PubMed         Abstract available


    J Clin Oncol

  24. GAO X, Garmezy B, Vuky J, Shen J, et al
    Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2026 Oct 9:JCO2502995. doi: 10.1200/JCO-25-02995.
    PubMed         Abstract available


    J Nucl Med

  25. SUN B, Werner D, Ni J, Weidle S, et al
    Preclinical Evaluation on the Radiohybrid Tandem [(18)F]La- and [(225)Ac]Ac-rhPSMA-10.1 for Targeted alpha-Therapy of Prostate Cancer.
    J Nucl Med. 2026 Oct 8:jnumed.126.273010. doi: 10.2967/jnumed.126.273010.
    PubMed         Abstract available


    J Urol

  26. FEUER Z, Wilson B, Bjurlin MA
    Multi-Cancer Early Detection Tests and Prostate Cancer Screening: Navigating the Gaps.
    J Urol. 2026 Oct 5:101097JU0000000000005340. doi: 10.1097/JU.0000000000005340.
    PubMed        

  27. SAAD F
    Implementing the 2026 AUA/SUO Guideline for Metastatic Castration-Resistant Prostate Cancer: What Is New, What Should Change, and What Comes Next.
    J Urol. 2026 Oct 9:101097JU0000000000005318. doi: 10.1097/JU.0000000000005318.
    PubMed        

  28. RIDOUANI F, Carbonell E, Santos Martin E, Yu R, et al
    Anatomical Mapping of Lymphatic Leakage Leading to Symptomatic Lymphoceles Formation After Pelvic Lymph Node Dissection for Prostate Cancer.
    J Urol. 2026 Oct 9:101097JU0000000000005342. doi: 10.1097/JU.0000000000005342.
    PubMed         Abstract available


    PLoS One

  29. AWAIS M, Rahman N, Javaid S, Wahab AT, et al
    Identification of new fucosyltransferase-8 inhibitors: An integrated biochemical, biophysical, and computational approach.
    PLoS One. 2026;21:e0349302.
    PubMed         Abstract available


    Prostate

  30. O'NEILL A, O'Keeffe R, Winter S, Dorrian J, et al
    Exploratory Analysis of Peri-Prostatic Adipose Tissue Radiomics Features and Their Potential to Predict Prostate Cancer Diagnosis: Results From a UK Biobank Study.
    Prostate. 2026 Oct 8. doi: 10.1002/pros.70226.
    PubMed         Abstract available

  31. MINAS TZ, Butler EN, Mwamburi SM, Dorsey TH, et al
    Stage-Specific Racial Disparities in Prostate Cancer Survival Outcomes.
    Prostate. 2026 Oct 6. doi: 10.1002/pros.70265.
    PubMed         Abstract available


    Urology

  32. HUANG K, Hall SJ, Vira M, Kutikov A, et al
    Who you see last matters: The recency effect in treatment decision-making for localized prostate cancer.
    Urology. 2026 Oct 8:S0090-4295(26)00637-0. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum